- Home
- TRIP vs CNTA Comparison
TRIP vs CNTA Comparison
Compare TRIP & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIP
- CNTA
- Stock Information
- Founded
- TRIP 2000
- CNTA 2020
- Country
- TRIP United States
- CNTA United Kingdom
- Employees
- TRIP N/A
- CNTA N/A
- Industry
- TRIP Computer Software: Programming Data Processing
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- TRIP Technology
- CNTA Health Care
- Exchange
- TRIP Nasdaq
- CNTA Nasdaq
- Market Cap
- TRIP 2.1B
- CNTA 2.2B
- IPO Year
- TRIP 2011
- CNTA 2021
- Fundamental
- Price
- TRIP $13.94
- CNTA $16.00
- Analyst Decision
- TRIP Hold
- CNTA Strong Buy
- Analyst Count
- TRIP 16
- CNTA 7
- Target Price
- TRIP $18.60
- CNTA $23.71
- AVG Volume (30 Days)
- TRIP 2.4M
- CNTA 463.7K
- Earning Date
- TRIP 11-06-2024
- CNTA 11-12-2024
- Dividend Yield
- TRIP N/A
- CNTA N/A
- EPS Growth
- TRIP N/A
- CNTA N/A
- EPS
- TRIP 0.26
- CNTA N/A
- Revenue
- TRIP $1,814,000,000.00
- CNTA $6,853,000.00
- Revenue This Year
- TRIP $3.97
- CNTA N/A
- Revenue Next Year
- TRIP $6.24
- CNTA N/A
- P/E Ratio
- TRIP $53.70
- CNTA N/A
- Revenue Growth
- TRIP 3.54
- CNTA N/A
- 52 Week Low
- TRIP $12.93
- CNTA $5.58
- 52 Week High
- TRIP $28.76
- CNTA $18.74
- Technical
- Relative Strength Index (RSI)
- TRIP 37.43
- CNTA 49.07
- Support Level
- TRIP $14.12
- CNTA $15.15
- Resistance Level
- TRIP $14.75
- CNTA $18.74
- Average True Range (ATR)
- TRIP 0.64
- CNTA 0.88
- MACD
- TRIP -0.27
- CNTA 0.10
- Stochastic Oscillator
- TRIP 1.04
- CNTA 35.68
About TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2023, 58% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 41% of sales in 2023, and TheFork, its dining brand, represented 9% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.